Hutch News
Results per Page:
Poor quality of life in 1 in 5 caregivers of bone marrow transplant survivors
Largest-ever study IDs risk factors, paves way for interventions to help
New insights into CAR T-cell therapy's potential side effects
<p>Detailed study of cytokine release syndrome and neurologic toxicities could help make emerging cancer immunotherapies safer</p>
Health disparities may affect end-of-life experiences of minority blood cancer patients
A new study finds ethnic and racial minorities with leukemia or lymphoma are more likely to die in hospital, receive aggressive care in last weeks of life than white patients
‘Remarkable’ distinctions in pediatric leukemia point toward improved treatment
Big new study in pediatric and young adult acute myeloid leukemia warns against ‘trickle-down therapeutics’
Dr. Stephanie Lee elected vice president of American Society of Hematology
Her one-year term will be followed by successive terms as president-elect and president
Good News: American Society of Hematology to recognize Dr. Oliver Press for outstanding mentorship
American Society of Hematology to recognize Dr. Oliver Press for outstanding mentorship
Promising results in trial of engineered T cells in high-risk leukemia
High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia
Bringing a leukemia treatment back to life with precision medicine
New research writes latest chapter in one drug's story
.jpg)
The quest to better understand the deadliest childhood leukemia
Oncologists are beginning to leverage unique genomic characteristics of pediatric AML to improve treatment and prognosis
Fred Hutch opens first-of-its kind Bezos Family Immunotherapy Clinic
Clinic will allow researchers to conduct twice as many immunotherapy trials, enable intensive patient monitoring to improve experimental therapies
Patients with advanced lymphoma in remission after T-cell therapy
New study: 7 of 11 trial participants who got two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission
93 percent of advanced leukemia patients in remission after immunotherapy
‘Exciting’ but early results from trial of engineered immune cells